GlassScriptPhysician profile
Misty A Cundiff
NPI 1497178347
$7,314.12
in general payments reported to CMS, 2019-2025
37 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,221 · 2022: $1,608 · 2023: $1,763 · 2024: $1,500 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,319 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,318.82 |
| Education | $165.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $765.79 | 2022-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $690.13 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $609.01 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $517.66 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $507.65 | 2021-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $431.20 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $377.01 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $266.02 | 2021-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $255.47 | 2021 | |
| Ironshore Pharmaceuticals INC. | $243.11 | 2022-2024 | Jornay Pm |
| Astellas Pharma US INC | $218.09 | 2022-2023 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $201.34 | 2022 | |
| Vanda Pharmaceuticals INC. | $194.26 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $188.98 | 2021-2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $177.29 | 2023-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $163.86 | 2021-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $158.74 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.76 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.91 | 2022-2025 | Trintellix |
| Amgen INC. | $120.76 | 2021-2025 | Tezspire, Repatha, Otezla |
| Axsome Therapeutics, INC. | $105.13 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $92.60 | 2022-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $86.08 | 2021-2022 | |
| Mylan Specialty L.P. | $85.93 | 2022-2024 | Yupelri |
| Alkermes, INC. | $80.95 | 2023-2024 | Lybalvi, Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.53 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $72.05 | 2022 | |
| Xeris Pharmaceuticals, INC. | $70.24 | 2022-2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $63.15 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $48.04 | 2023-2025 | Rexulti, Vyepti |
| Sunovion Pharmaceuticals INC. | $44.61 | 2021 | |
| Phathom Pharmaceuticals, INC. | $30.17 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $22.56 | 2023 | Quviviq |
| Dexcom, INC. | $20.20 | 2023 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $19.88 | 2024 | Evkeeza |
| Janssen Biotech, INC. | $17.43 | 2025 | Tremfya |
| Exact Sciences Corporation | $13.53 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Cundiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.